ClinicalTrials.gg
Enrolling by invitationNCT07659470PNEUMO-SMSUpdated Oct 22, 2026

Randomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile.

An interventional study of WhatsApp text message reminder for pneumococcal vaccination in Pneumococcal Infections, Immunization Programs and Vaccination Coverage, sponsored by Pablo Tomás Valenzuela García. Enrolling by invitation at 1 site in Chile. Open to participants aged 64 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Pablo Tomás Valenzuela García · Not applicable, Interventional, and Prevention

How we know

Updated Oct 22, 2026Now Enrolling by invitationStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40,753
Allocation
Randomized
Ages
64 Years to 65 Years
Sex
All
01

Study summary

The goal of this randomized controlled trial is to learn if text message reminders sent through WhatsApp increase pneumococcal vaccination coverage in adults turning 65 years old in Chile. The main questions it aims to answer are:

Do text message reminders increase the proportion of adults aged 65 years who receive the pneumococcal vaccine compared to usual care? Do text message reminders increase pneumococcal vaccination coverage within the first 7 days after the message is sent? Is there an association between socioeconomic factors and pneumococcal vaccination coverage in adults aged 65 years in Chile?

Researchers will compare adults who receive a text message reminder to adults who receive no reminder (usual care) to see if the reminders increase vaccination uptake.

Participants will:

Be randomly assigned to receive a WhatsApp text message reminder about the pneumococcal vaccine or to receive no reminder Receive a second reminder on day 14 if they have not yet been vaccinated (intervention group only) Be followed for 6 weeks, with vaccination status checked at days 7, 21, and 42 from the start of the intervention

Read the detailed description

Background and Rationale Streptococcus pneumoniae is a globally distributed pathogen responsible for a wide spectrum of diseases, with the highest burden concentrated in children under 5 years and adults over 50 years. In Chile, invasive pneumococcal disease represents a growing public health threat among older adults: between epidemiological weeks 1 and 30 of 2024, reported cases increased by 9% compared to the previous year, with adults aged 60 years and older accounting for 47.7% of all registered isolates.

Despite the availability of the 23-valent pneumococcal polysaccharide vaccine (PPV23) free of charge through Chile's National Immunization Program (Programa Nacional de Inmunizaciones, PNI) since 2007, vaccination coverage among adults turning 65 years has remained consistently insufficient. The cohort born in 1957 reached 25.6% coverage in 2022; the 1958 cohort reached 25.0% in 2023; and the 1959 cohort reached 30.1% in 2024. These figures fall well below established public health targets and reflect a structural gap that conventional communication strategies have failed to close.

Text message reminders have emerged as a promising intervention to improve vaccination coverage. They are low-cost, scalable, rapidly deployable, and applicable at the population level. The most recent systematic review and meta-analysis of randomized controlled trials on this topic demonstrated that text message reminders significantly increase vaccination coverage by 9% (95% CI: 6-13%), an effect that is consistent regardless of message content, country income level, or target population age. Chile offers particularly favorable conditions for this type of intervention, with over 30 million active mobile phones, 94.1% internet access, and 75% social media users, positioning it as one of the most digitally connected countries in Latin America.

Study Design Is an open-label, parallel-group, randomized controlled trial conducted within the operational framework of Chile's National Immunization Program. Adults born in 1961 who turn 65 years of age in 2026, have a valid mobile phone number registered in the National Immunization Registry (Registro Nacional de Inmunizaciones, RNI), and have no prior record of pneumococcal vaccination will be eligible for inclusion. Individuals identified as deceased in the RNI will be excluded.

From an estimated base cohort of 175,000 adults born in 1961, approximately 43,000 individuals are expected to meet the eligibility criteria and constitute the study population. All eligible individuals will be included by convenience sampling, with no additional active selection process. Participants will be randomized 1:1 to the intervention or control group using stratified randomization by sex and region of Chile.

The study will be conducted during July and August 2026, with a total follow-up period of six weeks per participant.

Intervention

Intervention group - text message reminder:

Participants assigned to the intervention group will receive a WhatsApp text message developed by the PNI communications team in collaboration with the Ministry of Health's Communications Unit, based on the Yale-UNICEF Vaccine Messaging Guide. The message will be sent by the Ministry of Health through Rayén Salud - the official provider of the RNI - using its artificial intelligence contactability platform EMILIA, which is the institutional and official contactability platform of the National Immunization Program.

The message will include: (1) an official presentation identifying the Ministry of Health of Chile as the sender; (2) a reminder that the recipient is eligible for free pneumococcal vaccination upon turning 65 years of age; (3) confirmation that the vaccine is guaranteed and available at no cost; and (4) the name, address, and operating hours of vaccination centers in the participant's municipality of residence.

The first message will be sent on day 0 of the intervention. Vaccination status will be verified at days 7 and 13. Participants who have not been vaccinated by day 13 will receive a second reminder message on day 14. All participants will be followed until day 42, at which point final vaccination status will be recorded. The date of vaccination will be registered for all participants who receive the vaccine during the study period.

Control group - usual care:

Participants assigned to the control group will not receive a text message reminder. They will be informed of the pneumococcal vaccination recommendation through the usual PNI communication channels, including written press, digital media, and official social media accounts of the Ministry of Health and the Undersecretary of Public Health. Vaccination status will be assessed at the same time points as the intervention group (days 7, 21, and 42), and the date of vaccination will be recorded for those vaccinated during the study period.

Outcomes The primary outcome is pneumococcal vaccination coverage at day 42 from the start of the intervention, defined as the proportion of randomized adults in each group who received the PPV23 vaccine during the follow-up period.

Secondary outcomes include:

  1. pneumococcal vaccination coverage at day 7 from the start of the intervention.
  2. pneumococcal vaccination coverage at day 21 from the start of the intervention.
  3. time from randomization to pneumococcal vaccination, analyzed using Kaplan-Meier survival analysis with log-rank testing.
  4. the association between sex or geographic region and pneumococcal vaccination coverage, estimated using a log-binomial regression model.

Data Sources and Management All data will be obtained exclusively from the RNI. The following variables will be collected: sex, municipality, region, influenza vaccination in the past year, text message assignment (yes/no), date of first text message, date of second text message (if applicable), pneumococcal vaccination (yes/no), and date of pneumococcal vaccination.

Data extraction, custody, and management will be the responsibility of the PNI's Data Management and Development Unit (Patricia Cabezas Olivares, Paulina Muñoz Cortés, Iván Brstilo Cerda), under the supervision of the Head of the National Immunization Program and the principal investigator. The final database will be anonymized by assigning a unique numeric code to each participant, dissociating personal identity from vaccination data and randomization group assignment. The linkage table will be stored separately on an encrypted server with restricted access and will be securely destroyed upon study completion. Results will be reported exclusively in aggregate form, with no possibility of direct or indirect participant identification. All data handling complies with Chilean Law No. 19,628 on the Protection of Private Life.

Statistical Analysis The statistical analysis will follow an intention-to-treat approach. Baseline characteristics will be described for each group; categorical variables will be expressed as absolute numbers and percentages, and continuous variables as mean and standard deviation or median and interquartile range according to distribution.

Pneumococcal vaccination coverage will be estimated at days 7, 21, and 42 for both groups, with the numerator defined as the number of vaccinated adults in each group and the denominator as the total number of randomized adults in each group. The association between the intervention and the outcome will be assessed using a chi-square test. The magnitude of the association will be expressed as relative risk with 95% confidence intervals. The number needed to message (NNM) will be calculated as the reciprocal of the absolute risk reduction.

Time-to-vaccination will be analyzed using Kaplan-Meier survival curves, with time zero defined as the date of randomization and the event of interest defined as pneumococcal vaccination. Participants not vaccinated by the end of follow-up will be censored at day 42. Differences between survival curves will be assessed using the log-rank test. The association between sex or geographic region and vaccination outcome will be estimated using a log-binomial model. All statistical analyses will be performed using RStudio (Version 2025.09.1+401) and Stata 18 (StataCorp, College Station, TX).

Sample Size An a priori power calculation was conducted to detect an absolute difference of 9% in vaccination coverage between the intervention and control groups. Assuming a baseline coverage of 10% in the control group and 19% in the intervention group, with a two-sided significance level of 0.05 and 21,500 participants per group, the estimated statistical power exceeds 99% using a two-proportion z-test.

Ethical Considerations This study will be submitted for review to the Research Ethics Committee of the Pontificia Universidad Católica de Chile. Given the minimal risk of the intervention, the programmatic nature of the study within the National Immunization Program, the operational impracticability of obtaining individual informed consent from approximately 43,000 geographically dispersed participants without introducing systematic selection bias, and the clear social and scientific value of the study, a waiver of individual informed consent will be formally requested. This request is grounded in CIOMS 2016 Guidelines (Guideline 10) and the Declaration of Helsinki. The study complies with Chilean Law No. 19,628 on the Protection of Private Life regarding the use of personal data for research purposes.

Funding This study is funded entirely through the budget of the National Immunization Program, under Subtitle 24 of Chile's Public Sector Budget Law for 2026. No private funding is involved.

02

Conditions studied

  • Pneumococcal Infections
  • Immunization Programs
  • Vaccination Coverage
  • Text Messaging (Intervention)
  • Reminder Systems
  • Health Promotion
  • Aged 65 Years or Older

Keywords

  • Pneumococcal vaccine
  • Vaccination coverage
  • Text message reminder
  • WhatsApp
  • Older adults
  • National Immunization Program
  • Randomized controlled trial
  • Health behavior nudge
  • Digital health intervention
  • Public health
  • Streptococcus pneumoniae
  • Behavioral intervention
  • Vaccine uptake
  • Low-cost intervention
  • Population-based intervention
  • Pneumococcal polysaccharide vaccine
  • Immunization registry
  • Latin America
  • Chile
03

In context

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

This study's planned enrollment of 40,753 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.

Browse Pneumococcal Infections studies →

Lead sponsor

This is the only study on the registry with Pablo Tomás Valenzuela García as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
64 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults born during the year 1961, turning 65 years of age in 2026
  • Resident in Chile at the time of the study
  • Valid mobile phone number registered in the National Immunization Registry (RNI)

Exclusion criteria

Exclusion Criteria:

  • Record of pneumococcal vaccination in the National Immunization Registry (RNI).
  • Identified as deceased in the Chilean Civil Registry and Identification Service.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40,753 participants (estimated)

Study arms

  • Experimental
    Text message reminder group

    Participants assigned to this arm will receive a WhatsApp text message reminder on day 0 of the intervention, sent by the Ministry of Health of Chile through the official National Immunization Program contactability platform (EMILIA, Rayén Salud). The message will include an acknowledgment that the participant is eligible for free pneumococcal vaccination upon turning 65 years of age, confirmation that the vaccine is available at no cost, and the name, address, and operating hours of vaccination centers in the participant's municipality of residence. A second reminder message will be sent on day 14 to participants who have not yet been vaccinated. Participants will be followed for 6 weeks, with vaccination status assessed at days 7, 21, and 42 from the start of the intervention.

    Behavioral: WhatsApp text message reminder for pneumococcal vaccination

  • No intervention
    Usual care group

    Participants assigned to this arm will not receive a text message reminder. They will be informed of the pneumococcal vaccination recommendation through the usual communication channels of the National Immunization Program, including written press, digital media, and official social media accounts of the Ministry of Health of Chile. Vaccination status will be assessed at days 7, 21, and 42 from the start of the intervention, using the National Immunization Registry (RNI) as the data source.

Interventions

  • BehavioralWhatsApp text message reminder for pneumococcal vaccination

    A text message reminder sent via WhatsApp on day 0 of the intervention by the Ministry of Health of Chile, through the official National Immunization Program contactability platform EMILIA (Rayén Salud). The message includes: (1) an official presentation identifying the Ministry of Health of Chile as the sender; (2) a reminder that the recipient is eligible for free pneumococcal vaccination upon turning 65 years of age; (3) confirmation that the 23-valent pneumococcal polysaccharide vaccine (PPV23) is guaranteed and available at no cost through the National Immunization Program; and (4) the name, address, and operating hours of vaccination centers in the participant's municipality of residence. A second reminder message with identical content will be sent on day 14 to participants in the intervention arm who have not yet received the vaccine. The message was developed by the National Immunization Program and the Ministry of Health Communications Unit, based on the Yale-UNICEF Vaccine M

06

What researchers measure

Primary outcomes

  1. Pneumococcal vaccination coverage at day 42

    Proportion of randomized adults in each group who received the 23-valent pneumococcal polysaccharide vaccine (PPV23) within 42 days from the start of the intervention. Vaccination status will be ascertained through the National Immunization Registry (RNI). Coverage will be calculated as the number of vaccinated adults divided by the total number of randomized adults in each group. The association between the intervention and the outcome will be assessed using a chi-square test, and the magnitude of the association will be expressed as relative risk with 95% confidence intervals.

    Time frame: 42 days from the start of the intervention

Secondary outcomes

  1. Pneumococcal vaccination coverage at day 7

    Proportion of randomized adults in each group who received the 23-valent pneumococcal polysaccharide vaccine (PPV23) within 7 days from the start of the intervention. Vaccination status will be ascertained through the National Immunization Registry (RNI). Coverage will be calculated as the number of vaccinated adults divided by the total number of randomized adults in each group.

    Time frame: 7 days from the start of the intervention

  2. Pneumococcal vaccination coverage at day 21

    Proportion of randomized adults in each group who received the 23-valent pneumococcal polysaccharide vaccine (PPV23) within 21 days from the start of the intervention. Vaccination status will be ascertained through the National Immunization Registry (RNI). Coverage will be calculated as the number of vaccinated adults divided by the total number of randomized adults in each group.

    Time frame: 21 days from the start of the intervention

  3. Time to pneumococcal vaccination

    The time elapsed from randomization to administration of the 23-valent pneumococcal polysaccharide vaccine (PPV23) was analyzed using the Kaplan-Meier survival method. Time zero was defined as the date of message dispatch. Participants who had not been vaccinated by the end of the follow-up period were censored on day 42. Differences in survival curves between the intervention and control groups were assessed using the log-rank test.

    Time frame: 42 days from the start of the intervention

  4. Association between sociodemographic factors and pneumococcal vaccination coverage

    Association between sociodemographic factors - specifically sex (male/female) and geographic region of residence (16 regions of Chile) - and pneumococcal vaccination coverage at day 42, estimated using a log-binomial regression model. Each factor will be analyzed independently. Results will be expressed as relative risk with 95% confidence intervals.

    Time frame: 42 days from the start of the intervention

07

Study locations

1 site
  • National Immunization Program, Ministry of Health, Chile.
    Santiago, RM 8320064, Chile
08

References and documents

Publications

  • Yale Institute for Global Health, & United Nations Children's Fund. (2020). Vaccine messaging guide. UNICEF. unicef.org
  • Data Reportal (2025), "Digital 2025: Chile", retrieved from https://datareportal.com/reports/digital-2025-chile on May 7th 2026.
  • Comité Asesor en Vacunas y Estrategias de Inmunización de Chile. Recomendación del CAVEI Sobre Vacunación Neumocócica [Internet]. Chile; noviembre de 2025 [citado 7 de mayo de 2026]. Disponible en: https://vacunas.minsal.cl/wp-content/uploads/2025/11/Recomendacion-del-CAVEI-sobre-vacunacion-antineumococica-1.pdf
  • Calvo M, Inostroza J, Bastias M, Dabanch J, Cerda J, Gonzalez C, Saldana A, Diaz E, Endeiza ML, Rodriguez J, Santillana S, Acevedo J. [CAVEI recommendation for pneumococcal vaccine use in adults]. Rev Chilena Infectol. 2020 Feb;37(1):47-50. doi: 10.4067/S0716-10182020000100047. No abstract available. Spanish. PubMed 32730400 ↗
  • Instituto de Salud Pública/MINSAL. Informe de Vigilancia enfermedad invasora por S. pneumoniae Chile 2024.
  • WHO. Considerations for pneumococcal vaccination in older adults. Wkly Epidemiol Rec 2021;96(23):217-228.
  • Louw GE, Hohlfeld AS, Kalan R, Engel ME. Mobile Phone Text Message Reminders to Improve Vaccination Uptake: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2024 Oct 8;12(10):1151. doi: 10.3390/vaccines12101151. PubMed 39460318 ↗
  • Scelfo C, Menzella F, Fontana M, Ghidoni G, Galeone C, Facciolongo NC. Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance. Vaccines (Basel). 2021 Apr 22;9(5):420. doi: 10.3390/vaccines9050420. PubMed 33922273 ↗

Individual participant data

Plan to share: No — Individual participant data contain personal identifiers obtained from a national administrative registry (RNI) protected under Chilean Law No. 19,628 on the Protection of Private Life. Sharing of individual participant data is therefore not legally permissible. Aggregate results will be available upon publication of the study findings.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Jul 2026 → Oct 2026, primary completion Sep 2026 → Nov 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartActual
Oct 1, 2026was Jul 2026
Primary completionEst.
Nov 13, 2026was Sep 2026
CompletionEst.
Dec 31, 2026was Oct 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 22, 2026
Start date
Jul 15, 2026→Oct 1, 2026 (actual)
Oct 22, 2026
Primary completion
Sep 1, 2026→Nov 13, 2026
Oct 22, 2026
Study completion
Oct 1, 2026→Dec 31, 2026
Oct 22, 2026
Enrollment
43000→40753
Oct 22, 2026
Contact
No study contact listed any more: removed p•••@uc.cl · •••3508; removed i•••@minsal.cl · •••0355
Oct 22, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • National Immunization Program, Ministry of Health, Chile. · Santiago, ChileContact removed i•••@minsal.clContact removed p•••@uc.clContact removed (no phone or email listed)Contact removed (no phone or email listed)Contact removed (no phone or email listed)
Oct 22, 2026
Title
RANDOMIZED CONTROLLED TRIAL OF TEXT MESSAGE TO INCREASE PNEUMOCOCCAL VACCINATION IN ADULTS IN CHILERandomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile.
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Jul 15, 2026→Oct 1, 2026 (now actual)
    Primary completion Sep 1, 2026→Nov 13, 2026
    Study completion Oct 1, 2026→Dec 31, 2026
    Enrollment 43000→40753
    Contact No study contact listed any more: removed p•••@uc.cl · •••3508; removed i•••@minsal.cl · •••0355
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Immunization Program, Ministry of Health, Chile. · Santiago, ChileContact removed i•••@minsal.clContact removed p•••@uc.clContact removed (no phone or email listed)Contact removed (no phone or email listed)Contact removed (no phone or email listed)
    Title RANDOMIZED CONTROLLED TRIAL OF TEXT MESSAGE TO INCREASE PNEUMOCOCCAL VACCINATION IN ADULTS IN CHILERandomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07659470
Lead sponsor
Pablo Tomás Valenzuela García
Collaborators
Ministry of Health, Chile
Responsible party
Pablo Tomás Valenzuela García (Specialist in Adult Infectious Diseases and Epidemiologist, UC. Advisor to the National Immunization Program, Ministry of Health, Chile., Pontificia Universidad Catolica de Chile) — Sponsor-investigator
First posted
Jun 22, 2026
Start date
Oct 1, 2026
Primary completion
Nov 13, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 22, 2026

Study contacts

Pablo Valenzuela García, MD, MSc
principal investigator · Pontifical Catholic University of Chile. National Immunization Program, Ministry of Health, Chile.
Ignacio Castro Aguirre, MD; MPH
study director · National Immunization Program, Ministry of Health, Chile.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion